Stockreport

ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) [Seeking Alpha]

ADC Therapeutics SA Common Shares  (ADCT) 
PDF The company's prospects are now uncertain as they face challenges in getting a foothold for their approved antibody-drug conjugate. The success of the phase 3 trial f [Read more]